According to the 2021 Chinese Guidelines and Norms for the Diagnosis and Treatment of Breast Cancer, Patients with HER2-positive breast cancer who have completed trastuzumab treatment and are at risk of recurrence may be considered for 1 year of neratinib intensive therapy, Here is a detailed instruction of neratinib on the FDA website (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf). Here, ERBB2 is linked to breast carcinoma.